Novus therapeutics, inc. (NVUS)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Operating activities
Net loss

-8,177

-4,144

-2,893

-4,093

-4,881

-4,574

-3,496

-3,189

-2,806

-2,110

-2,970

-6,662

-1,374

-3,737

-9,270

-13,526

-11,426

-11,017

-11,853

-8,957

-13,260

-6,208

-6,390

-5,851

-4,847

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

2

2

3

2

2

3

3

2

3

4

2

12

4

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of operating lease asset

44

44

43

43

43

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Warrant inducement expense

4,829

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation

437

243

227

627

211

740

238

404

161

193

150

130

106

342

646

992

1,022

857

804

606

634

589

1,179

250

90

Depreciation expense

-

-

-

-

-

-

-

-

-

-

-

-

-

17

49

52

53

56

32

16

5

5

5

7

4

Release of reserve for loan to former advisor

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

15

34

45

34

34

45

Amortization of premium on marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-6

-33

-39

-37

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other assets

-159

-351

-63

163

-103

453

-169

384

-192

-244

-406

1,174

-7

379

-643

-478

-521

-549

200

1,392

-85

995

671

-180

344

Accounts payable and accrued expenses

552

-342

-291

-1,296

537

931

151

-167

179

-960

-1,005

-368

375

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liability

-43

-44

-41

-42

-38

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-2,197

-2,023

-2,889

-4,922

-4,023

-3,353

-2,935

-3,334

-2,271

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-456

-960

-40

678

-444

-18

-1,764

2,669

-1,124

1,377

-291

798

Accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,069

-513

1,680

-663

1,047

1,065

522

-1,158

1,297

20

389

-432

Other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

45

-

-

-

-

Other long-term liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-36

-36

30

38

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-882

-7,310

-9,173

-10,297

-9,740

-8,877

-10,250

-11,005

-11,104

-6,460

-4,464

-5,421

-4,776

Financing activities
Purchase of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

17

216

157

147

45

0

7

6

12

Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

11,903

15,647

8,150

-17

-316

-15,854

-24,295

-45

0

-157

-6

-12

Proceeds from issuances of common stock, net

-

0

0

9,569

107

1

-1

0

7,491

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of warrants, net

5,191

-

-

-

-

-

-

-

-

0

0

2,719

400

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

37

48

188

207

21

4

0

8

4

Net cash provided by financing activities

5,191

0

0

9,569

107

1

70

0

7,491

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of notes receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

15

34

45

34

34

45

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

400

0

0

0

37

48

188

222

55

6,252

88,935

-437

49

Net change in cash

2,994

-2,023

-2,889

4,647

-3,916

-3,352

-2,865

-3,334

5,220

-1,861

-3,417

21,946

-482

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

4,593

6,474

-2,147

-9,720

-9,145

-25,916

-35,078

-11,094

-208

84,314

-5,864

-4,739

Deferred offering costs included in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

98